| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/14789450.2016.1217775 |
| P698 | PubMed publication ID | 27459711 |
| P50 | author | Luis M Blanco-Colio | Q55542660 |
| Sebastian Mas | Q56670615 | ||
| Oscar Lorenzo | Q58836396 | ||
| Coral Barbas | Q28745544 | ||
| José Tuñón | Q43265181 | ||
| P2093 | author name string | Jesús Egido | |
| Elena Burillo | |||
| José Luis Martín-Ventura | |||
| Francisco Javier Rupérez | |||
| P2860 | cites work | Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease | Q46557284 |
| Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease | Q46870147 | ||
| Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease | Q46872805 | ||
| Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure | Q48421210 | ||
| A metabolomic profile is associated with the risk of incident coronary heart disease. | Q50653885 | ||
| A novel targeted proteomics method for identification and relative quantitation of difference in nitration degree of OGDH between healthy and diabetic mouse. | Q51050871 | ||
| The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. | Q51093087 | ||
| ¹H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. | Q53446586 | ||
| Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease | Q57446095 | ||
| Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms | Q57446117 | ||
| Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio | Q57767325 | ||
| Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure | Q58071197 | ||
| Proteomic analysis of human vessels: Application to atherosclerotic plaques | Q59315364 | ||
| Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury | Q24657261 | ||
| Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL | Q24669594 | ||
| Exosomes Mediate the Intercellular Communication after Myocardial Infarction | Q26768620 | ||
| Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis | Q26797260 | ||
| Metabolomics and cardiovascular biomarker discovery | Q26991473 | ||
| Proteomics investigations of HDL: challenges and promise | Q27000995 | ||
| Novel methodologies for biomarker discovery in atherosclerosis | Q28088373 | ||
| Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin | Q28249401 | ||
| TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis | Q28257134 | ||
| Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction | Q28386460 | ||
| Hearts from mice fed a non-obesogenic high-fat diet exhibit changes in their oxidative state, calcium and mitochondria in parallel with increased susceptibility to reperfusion injury | Q28388331 | ||
| Analysis of proteins and proteomes by mass spectrometry | Q30676361 | ||
| Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. | Q30702642 | ||
| Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions | Q33195220 | ||
| Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis | Q33204658 | ||
| Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins | Q33215030 | ||
| Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. | Q33271422 | ||
| Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis | Q33271663 | ||
| Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques | Q33276736 | ||
| A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications | Q33286687 | ||
| Silent myocardial ischemia is associated with altered plasma phospholipids | Q33399462 | ||
| Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques | Q33520612 | ||
| A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approach | Q33655192 | ||
| Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 | ||
| Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm | Q33805812 | ||
| Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation | Q33944773 | ||
| Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. | Q34152435 | ||
| Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry | Q34206870 | ||
| Effects of dalcetrapib in patients with a recent acute coronary syndrome | Q34309967 | ||
| Next-generation proteomics: towards an integrative view of proteome dynamics. | Q34315255 | ||
| Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra | Q34405268 | ||
| High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies | Q34496492 | ||
| Multiple biomarkers for the prediction of first major cardiovascular events and death | Q34593507 | ||
| Novel parallelized quadrupole/linear ion trap/Orbitrap tribrid mass spectrometer improving proteome coverage and peptide identification rates. | Q34657660 | ||
| Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes | Q34751855 | ||
| Proteomic changes in the heart of diet-induced pre-diabetic mice | Q34847102 | ||
| The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease | Q35090717 | ||
| Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions | Q35149530 | ||
| Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts | Q35152158 | ||
| Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function | Q35219088 | ||
| A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours | Q35337546 | ||
| Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease | Q35531002 | ||
| Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis | Q35615662 | ||
| Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. | Q35892530 | ||
| Altered heart proteome in fructose-fed Fisher 344 rats exposed to bisphenol A. | Q35940784 | ||
| Candidate-based proteomics in the search for biomarkers of cardiovascular disease | Q35990040 | ||
| Characterization of membrane-shed microvesicles from cytokine-stimulated β-cells using proteomics strategies | Q36144112 | ||
| The assessment of endothelial function: from research into clinical practice | Q36190146 | ||
| High dietary fat selectively increases catalase expression within cardiac mitochondria | Q36543813 | ||
| Cells release subpopulations of exosomes with distinct molecular and biological properties | Q36638253 | ||
| Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. | Q36686970 | ||
| Human plasma platelet-derived exosomes: effects of aspirin | Q36812072 | ||
| Investigation of the Protective Effects of Phlorizin on Diabetic Cardiomyopathy in db/db Mice by Quantitative Proteomics | Q36825677 | ||
| Using antibody arrays to detect microparticles from acute coronary syndrome patients based on cluster of differentiation (CD) antigen expression | Q37154459 | ||
| Application of metabolomics to cardiovascular biomarker and pathway discovery | Q37206431 | ||
| Multi-dimensional co-separation analysis reveals protein-protein interactions defining plasma lipoprotein subspecies. | Q37289377 | ||
| Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. | Q37335886 | ||
| Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks | Q37341425 | ||
| Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. | Q37374980 | ||
| Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease | Q37415728 | ||
| Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. | Q37568751 | ||
| Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. | Q37583506 | ||
| Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach | Q37623655 | ||
| High-density lipoprotein: a potent inhibitor of inflammation | Q37636513 | ||
| The value of carotid intima-media thickness for predicting cardiovascular risk | Q37641573 | ||
| Proteomic strategies in the search of new biomarkers in atherothrombosis | Q37743950 | ||
| High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis | Q37783845 | ||
| The protein cargo of HDL: Implications for vascular wall biology and therapeutics | Q37803127 | ||
| Translating metabolomics to cardiovascular biomarkers | Q38028672 | ||
| A practical guide to metabolomic profiling as a discovery tool for human heart disease | Q38066622 | ||
| Chromosome-centric approach to overcoming bottlenecks in the Human Proteome Project | Q38068929 | ||
| Label-free quantification in clinical proteomics | Q38097312 | ||
| Microvesicles as cell-cell messengers in cardiovascular diseases | Q38179330 | ||
| High-density lipoprotein as a modulator of platelet and coagulation responses | Q38217201 | ||
| HDL in innate and adaptive immunity. | Q38220759 | ||
| The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases | Q38268586 | ||
| Cholesterol efflux and reverse cholesterol transport | Q38293439 | ||
| The HDL proteome in acute coronary syndromes shifts to an inflammatory profile | Q38501154 | ||
| Extracellular vesicles as new pharmacological targets to treat atherosclerosis | Q38542667 | ||
| Two-dimensional gel electrophoresis in proteomics: a tutorial | Q39739742 | ||
| Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events | Q39918198 | ||
| Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation | Q40006523 | ||
| In vitro biomarker discovery for atherosclerosis by proteomics | Q40501649 | ||
| Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics | Q41061522 | ||
| Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. | Q41436462 | ||
| Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator | Q42784912 | ||
| Protein sets define disease states and predict in vivo effects of drug treatment | Q43097124 | ||
| Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints | Q43265141 | ||
| Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. | Q43576623 | ||
| Label-free quantitative proteomic analysis of human plasma-derived microvesicles to find protein signatures of abdominal aortic aneurysms | Q44164516 | ||
| Proteomic analysis of hearts from Akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy. | Q44391060 | ||
| Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome | Q46084549 | ||
| Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms. | Q46208071 | ||
| P433 | issue | 9 | |
| P921 | main subject | biomarker | Q864574 |
| metabolomics | Q12149006 | ||
| P304 | page(s) | 857-871 | |
| P577 | publication date | 2016-08-05 | |
| P1433 | published in | Expert Review of Proteomics | Q15749465 |
| P1476 | title | Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential | |
| P478 | volume | 13 |
| Q90444009 | Cardiac function dependence on carbon monoxide |
| Q33705752 | Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. |
| Q33762042 | Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer |
Search more.